Cardiac Surgery With Cardiopulmonary Bypass Clinical Trial
Official title:
Sysytematic Evaluation of Heparin and Protamine in Cardiac Surgery
The precise amount of protamine required to neutralize unfractionated heparin (UFH) remains unknown. This study will systematically identify the doze needed to neutralize UFH following cardiopulmonary bypass (CPB).
The precise dose of protamine needed to neutralize unfractionated heparin (UFH) is unknown.
Research suggests that low dose protamine is associated with decreased need for transfusions
in cardiac surgery. The ATS guidelines recommend that half of the total UFH dose given for
cardiopulmonary bypass (CPB) should be neutralized with protamine. However, it is unknown if
this is routinely followed by anesthesiologists. Furthermore, the reference standard for UFH
has changed recently and it is unknown how this has affected the dose of protamine in the
perioperative period. Protamine does have a very short life and heparin rebound occurs very
commonly.
It is common practice to divert the suctioned mediastinal blood following CPB while the
patient is still anticoagulated. The traditional practice is that once half dose protamine
has been given, suction to the cardiotomy reservoir is turned off. All surgical field blood
loss is then diverted to wall suction. The inherent risk of letting too much protamine into
the CPB reservoir is that UFH therein may get neutralized and predispose to clot formation in
the venous reservoir. This precludes an emergency 'crash' on to CPB, should that be required
for some reason. Experience of the Investigators indicates that most surgeons will turn off
suction leading to the cardiotomy reservoir once half the total protamine dose has been
administered. The concern with this is that "half dose" protamine may be quite different for
different anesthesiologists.
The research investigators hypothesize low dose protamine is sufficient to neutralize the
effects of UFH as monitored through activated clotting time (ACT). Anesthesiologists
administer varying doses of protamine to neutralize UFH in cardiac surgery and the rationale
behind such decisions is unclear.
Thus, the primary objective of this study is to evaluate the dose of protamine required to
neutralize UFH following CPB. Secondary objectives are 1) to assess the amount of protamine
needed to neutralize UFH in intravenously administered cardiotomy reservoir blood. 2) To
examine the amount of residual heparin postoperatively in the cardiac surgery ICU; 3) to
examine, through semi-structured interviews, the decision-making processes involved in
managing (anti)coagulation in cardiac surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02900313 -
Serum Phosphatemia Predictive Marker for AKI Diagnosis After Cardiac Surgery
|
N/A | |
Active, not recruiting |
NCT06365827 -
Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)
|
||
Completed |
NCT04769752 -
Beta Blocker Use in Cardiac Surgery and Association With Postoperative Course
|
||
Completed |
NCT01561651 -
Left Atrial Appendage Occlusion Study III
|
N/A | |
Completed |
NCT00467181 -
A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery
|
Phase 2 | |
Not yet recruiting |
NCT06332547 -
Transfusion in Cardiac Valve Surgery
|
N/A |